• Insulin underuse due to costs remains high in primary care settings

    2 monthes ago - By Healio

    In a recent survey, nearly half of primary care patients with type 1 or type 2 diabetes reported suboptimal insulin use due to costs.
    According to Tess Willcoxon, a student at East Tennessee State University Bill Gatton College of Pharmacy, and Rick Hess, PharmD, CDCES, BCACP, an associate professor at the same institution, previous research has shown that high costs of insulin contribute to a lack of patient treatment. For example, a 2019 JAMA Internal Medicine study found that 25% of patients with diabetes receiving care at an endocrinology clinic reported cost-related insulin underuse.
    “It
    Read more ...

     

  • Is universal screening for type 1 diabetes ready for prime time?

    Is universal screening for type 1 diabetes ready for prime time?

    2 monthes ago - By Healio

    A few months ago, I would have questioned the value of universal screening for type 1 diabetes because we did not have anything to offer people who are at risk for the disease. However, we now have a drug - teplizumab-mzwv - that can delay the onset of type 1 diabetes. That is an important advance.
    The Fr1da study in Bavaria, Germany, has shown that the risk for type 1 diabetes for people who test autoantibody-positive is basically the same as relatives of people with type 1 diabetes who test autoantibody-positive, and most people who will develop type 1 diabetes do not have a
    Read more ...

     

  • Type 1 diabetes screening reaches ‘potentially pivotal moment' with new treatment option

    Type 1 diabetes screening reaches ‘potentially pivotal moment' with new treatment option

    2 monthes ago - By Healio

    The benefits of type 1 diabetes screening have long been up for debate, but FDA approval of the first therapy to delay the disease's onset may be changing the conversation.
    In November, the FDA approved teplizumab-mzwv to delay the onset of type 1 diabetes for both adults and children aged 8 years and older with stage 2 type 1 diabetes. Previously, physicians could identify people at high risk for the disease but were unable to provide a treatment to those who have not yet progressed to full-blown diabetes.
    “The FDA approval of teplizumab will change the
    Read more ...